Annemieke V. D. P. P.
- Country
- The Netherlands
- Department
- Oncology
Research Overview
- Evaluation of Image-Guided De-Escalation of Neoadjuvant Chemotherapy with Trastuzumab, Pertuzumab, and Drug Combination in HER2-Positive Breast Cancer
- Evaluation of CDK4/6 Inhibitors Abemaciclib, Palbociclib, and Ribociclib in HR+/HER2- Metastatic Breast Cancer: A Randomized Clinical Trial
- Efficacy and Safety of Fezolinetant in Treating Vasomotor Symptoms in Hormone Receptor-Positive Breast Cancer Patients on Adjuvant Endocrine Therapy
Data & Insights
Has run more than one trial at 53 of 146 partner sites.
Specializations
Advanced Breast Cancer Treatment
The investigator specializes in developing innovative treatments for hormone receptor-positive (HR+) breast cancer, with particular emphasis on combination therapies involving CDK 4/6 inhibitors and endocrine therapy approaches.
- Targeted Combination Therapies
- Endocrine Resistance Management
- Treatment Sequencing Strategies
Focuses on optimizing treatment sequences for maximum therapeutic benefit in advanced disease settings.
HER2-Positive Breast Cancer
Conducts research in HER2-positive breast cancer treatment, particularly exploring neoadjuvant chemotherapy optimization and dual HER2-blockade approaches using innovative imaging techniques.
- Image-Guided Treatment
- Chemotherapy De-escalation
- Targeted HER2 Therapies
Investigates personalized approaches to reduce treatment intensity while maintaining efficacy.
Triple-Negative Breast Cancer
Specializes in developing treatments for triple-negative breast cancer (TNBC), with focus on biomarker-driven therapy selection and novel combination approaches including immunotherapy.
- Biomarker Research
- Platinum-Based Therapies
- Immunotherapy Integration
Explores predictive testing strategies to optimize treatment selection in metastatic settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.